We are live on !
Find out more
SC
Stempoint Capital Portfolio holdings
AUM
$581M
Turnover
56.9%
1-Year Est. Return
373.68%
This Fund
S&P 500
This Quarter Est. Return
+35.11%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$58.2M
(+11%)
Cap. Flow
-$54.7M
Cap. Flow % of AUM
Cap. Flow %
-9.43%
Top 10 Holdings %
Top 10 Hldgs %
40.99%
Holding
116
New
34
Increased
19
Reduced
30
Closed
32
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.5
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$25.3M |
| 2 |
Erasca
ERAS
|
+$19M |
| 3 |
Tyra Biosciences
TYRA
|
+$14.5M |
| 4 |
First Tracks Biotherapeutics
TRAX
|
+$11.6M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$38.5M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
+$28.4M |
| 3 |
Revolution Medicines
RVMD
|
+$17.8M |
| 4 |
MBX Biosciences
MBX
|
+$14.9M |
| 5 |
Immunovant
IMVT
|
+$14.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.23% |
| 2 | Miscellaneous | 0.45% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Crescent Biopharma
CBIO
$459M
| $3.28M | 0.57% |
+182,382
| New | +$3.56M |
2026 Q2
0 quarters
|
|
52
Arrowhead Research
ARWR
$8.08B
| $3.2M | 0.55% |
+39,198
| New | +$2.9M |
2026 Q2
0 quarters
|
|
53
Kodiak Sciences
KOD
$5.74B
| $2.96M | 0.51% |
+75,872
| New | +$2.95M |
2026 Q2
0 quarters
|
|
54
Pharvaris
PHVS
$2.09B
| $2.8M | 0.48% |
80,907
-5,730
| -7% | -$173K |
2025 Q4
2 quarters
|
|
55
Monopar Therapeutics
MNPR
$480M
| $2.79M | 0.48% |
+30,125
| New | +$1.86M |
2026 Q2
0 quarters
|
|
56
Rapport Therapeutics
RAPP
$1.37B
| $2.77M | 0.48% |
+66,582
| New | +$2.45M |
2026 Q2
0 quarters
|
|
57
NewAmsterdam Pharma
NAMS
$2.45B
| $2.63M | 0.45% |
77,589
-103,069
| -57% | -$3.4M |
2025 Q1
5 quarters
|
|
58
Sionna Therapeutics
SION
$181M
| $2.61M | 0.45% |
59,426
+22,886
| +63% | +$916K |
2026 Q1
1 quarter
|
|
59
Arcutis Biotherapeutics
ARQT
$4.01B
| $2.59M | 0.45% |
98,945
-314,847
| -76% | -$7.33M |
2023 Q4
10 quarters
|
|
60
C4 Therapeutics
CCCC
$356M
| $2.45M | 0.42% |
523,648
+70,412
| +16% | +$241K |
2026 Q1
1 quarter
|
|
61
Spruce Biosciences
SPRB
$116M
| $2.23M | 0.39% |
41,388
+35,028
| +551% | +$1.96M |
2026 Q1
1 quarter
|
|
62
Cue Biopharma
CUE
$117M
| $2.11M | 0.36% |
+66,995
| New | +$1.51M |
2026 Q2
0 quarters
|
|
63
Structure Therapeutics
GPCR
$1.57B
| $2.05M | 0.35% |
38,178
-162,089
| -81% | -$7.17M |
2025 Q3
3 quarters
|
|
64
Protagonist Therapeutics
PTGX
$8.7B
| $2M | 0.34% |
16,303
-56,274
| -78% | -$5.88M |
2024 Q4
6 quarters
|
|
65
Helix Acquisition Corp III
HLXC
$228M
| $1.83M | 0.31% |
171,671
-133,357
| -44% | -$1.37M |
2026 Q1
1 quarter
|
|
66
Biodesix
BDSX
$247M
| $1.58M | 0.27% |
70,000
-4
| -0% | -$59 |
2026 Q1
1 quarter
|
|
67
Tenax Therapeutics
TENX
$56.9M
| $1.4M | 0.24% |
96,273
-92,427
| -49% | -$1.18M |
2026 Q1
1 quarter
|
|
68
SAB Biotherapeutics
SABS
$237M
| $1.34M | 0.23% |
342,631
-32,369
| -9% | -$120K |
2025 Q4
2 quarters
|
|
69
CalciMedica
CALC
$6.96M
| $1.2M | 0.21% |
+248,973
| New | +$883K |
2026 Q2
0 quarters
|
|
70
LB Pharmaceuticals
LBRX
$1.25B
| $1.03M | 0.18% |
31,785
-18,215
| -36% | -$535K |
2026 Q1
1 quarter
|
|
71
Cellectar Biosciences
CLRB
$10.6M
| $987K | 0.17% |
+354,938
| New | +$993K |
2026 Q2
0 quarters
|
|
72
CALL
Personalis
PSNL
$1.7B
| $811K | 0.14% |
+470,000
| New | +$3.83M |
2026 Q2
0 quarters
|
|
73
ProQR Therapeutics
PRQR
$185M
| $802K | 0.14% |
+431,054
| New | +$710K |
2026 Q2
0 quarters
|
|
74
CALL
Biohaven
BHVN
$1.71B
| $525K | 0.09% |
+500,000
| New | +$5.38M |
2026 Q2
0 quarters
|
|
75
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
| $400K | 0.07% |
+250,000
| New | +$33.8M |
2026 Q2
0 quarters
|
|
Similar funds
PM
RIS
GFI
CCWM
MFS
MIP
CA
LCM
Stempoint Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Stempoint Capital held 116 positions worth $581M, up 11% from $522M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Stempoint Capital withdrew a net $54.7M in Q2 2026, closing 32 positions and reducing 30 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $28.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Stempoint Capital opened a new position in First Tracks Biotherapeutics worth $12.5M.
- Stempoint Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 622,723 shares worth $12.5M.
- Stempoint Capital added most to Tango Therapeutics in Q2 2026, an estimated $25.3M increase.
- Stempoint Capital's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $38.5M.
- Stempoint Capital fully exited Syndax Pharmaceuticals in Q2 2026, selling an estimated $28.4M.
- Stempoint Capital's ten largest holdings make up 41% of its $581M portfolio in Q2 2026.
- Stempoint Capital opened 34 new positions and closed 32 in Q2 2026.
- Stempoint Capital's portfolio value rose 11% quarter-over-quarter to $581M.
Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.